22,401 Shares in Amedisys, Inc. $AMED Bought by Strs Ohio

Strs Ohio acquired a new stake in Amedisys, Inc. (NASDAQ:AMED) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,401 shares of the health services provider’s stock, valued at approximately $2,075,000. Strs Ohio owned 0.07% of Amedisys at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in AMED. Hexagon Capital Partners LLC raised its position in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 161 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 120 shares during the period. Fifth Third Bancorp raised its position in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock valued at $32,000 after purchasing an additional 141 shares during the period. UMB Bank n.a. raised its position in Amedisys by 100.0% in the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock valued at $36,000 after purchasing an additional 193 shares during the period. Finally, MRP Capital Investments LLC raised its position in Amedisys by 88.9% in the first quarter. MRP Capital Investments LLC now owns 595 shares of the health services provider’s stock valued at $55,000 after purchasing an additional 280 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.50.

Amedisys Stock Up 0.0%

NASDAQ:AMED opened at $101.01 on Tuesday. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of 39.30, a price-to-earnings-growth ratio of 1.34 and a beta of 0.89. Amedisys, Inc. has a one year low of $82.15 and a one year high of $101.02. The stock has a 50-day simple moving average of $99.65 and a 200 day simple moving average of $96.07. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.36.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.15. The business had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. Amedisys had a return on equity of 12.91% and a net margin of 3.56%.The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the firm earned $0.98 earnings per share. Sell-side analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.